August 8, 2024

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Madam/ Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We would like to inform you that Management of Strides will be attending investor conference organised by Emkay Global Financial Services Limited on August 12, 2024 at 10:00 hrs in Mumbai.

Earnings deck of Q1 FY25 (which was intimated/ uploaded on Stock Exchange/ Company website on July 29, 2024) and latest investor presentation available on Company website shall be the discussion documents during these meetings. The same is enclosed for ready reference.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited,**

MANJULA R
Digitally signed by MANJULA R
Date: 2024.08.08 11:00:53 +05'30'

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Strides

Strides Pharma Science Ltd

Feb 2024

Safe Harbor

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements“. These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Strides Reset Completed, Now Poised for Growth

(In INR Crores)	FY22	FY23	YoY %	9MFY24	YoY %*
Revenue	**3,095**	**3,704**	***+20%***	**2,997**	***+17%***
Gross Margin	*51.5%*	*56.1%*	*+463bps*	*59.2%*	*+300 bps*
Employee Cost	647	732	*+13%*	552	*1%*
Operating Cost	931	899	*-3%*	677	*8%*
Total Cost	**1,578**	**1,631**	***+3%***	**1,229**	***-4%***
EBITDA	**4.2**	**446**	*N/A*	**544**	***+147%***
EBITDA Margin%	*0.1%*	*12.0%*	*+1190bps*	*18.1%*	*+791bps*

Particulars	FY22	FY23	9MFY24
Net Debt / EBITDA	N/A	5.4x	**3x**
Net Working Capital Cycle	152	140	**136**

Consistent Revenue growth of high teens over last 18months

- Significant pick-up in B2B business via **synergICE**
- New Product Launches in the **Front-end business via Chestnut Ridge**
- Expansion of product offerings to **new geographies** through **portfolio maximization**

Gross Margin Revival — **Nearing historical levels of ~60%** driven by Ramp-up in US business and Easing of Supply chain disruption

Cost Efficiency: Operating Cost base brought down to $ 200m p.a.

- **FY22 Cost Base:** $230 M
- **FY23:** $202 M
- **FY24:** ~$200 M

- Reduction in **Logistics & Warehousing** Cost
- Reduction in Manufacturing **Under recoveries**
- Optimizing R&D Cost

Successful Deleveraging — **Net Debt to EBITDA reduced from ~8.3x in Q1FY23 to 3x by Q3FY24**

** 9MFY24 YoY growth adjusted for UCL, Kenya operations which got deconsolidated effective Sep 30th 2022*

Way Forward for Strides Excluding Soft Gelatin Capsule Business (Divested to OneSource)

Mid-Teens Revenue Growth + EBITDA Margin Expansion + Capital Efficiency = Improving ROCE towards 20%+ levels



**Adjusted for softgel business moving to OneSource*

Strides at a Glance: A Pharma Formulation Exports Player

	9MFY24 Annualized
Revenue	~$485 M
Gross Margin	~59%
EBITDA	~$88 M
EBITDA Margins	~18.1%
Net Debt / EBITDA	3x



Manufacturing Footprint
7 Mfg. Plants including
4 USFDA approved facilities

Quality Compliance
Successful compliance track record with Global regulatory agencies over the years

Globally Diversified
4600+ Workforce with exports to **100+** Countries

US remains a focus market for Strides; Reset for Profitable Growth







Large Approved Portfolio provides sufficient Leeway to Scale up the US Business

Existing Portfolio Strength

260+ ANDAs filed
235+ ANDA Approvals

65+ Commercial products

Ranked #1 in 19 Products &
Ranked among **Top 3 in 34 products**,
that contribute **75% of its U.S. Revenue**

Growth Levers in Place

Pipeline of 100+ Approved products of which **50+ products to be launched over the next 36 months**

New domain additions comprising of Controlled Substances, Hormones, and Nasal Sprays through Chestnut Ridge

Targeting few High-ticket Launches:
$15M-$20M per product
(vs. $5M-$7M historically)



Targeting a Revenue of
$400 million
within the next 3 Yrs

Strides among the Leading Indian Players in the US Market





**Strides Q3FY24 US Revenues Annualized at $269 m*
 # Growth is based on CAGR from FY22 to H1FY24

Strides has a differentiated strategy for its US Business – Market Leadership in Niche Products

- Unlike other Generic Pharma Players, Strides has **Profitably** established its US business by implementing a Calibrated strategy for product launches, maintaining **pricing discipline** & **preserving its margin** profile.
- Despite facing a challenging environment in the US, this strategy has enabled the company to **maintain its $250 million business outlook**.
- With Approved Manufacturing Facilities and R&D Investments largely done, Strides possesses an extensive portfolio of approved products. This should help us **launch 50+ products**, thereby propelling us toward the **$400 million** target for the US business within the **next 3 years**.
- Strides' emphasis in its US business lies not in rapid growth, but rather in **prioritizing margins, compliance, and ensuring a steady supply**. The extensive pipeline of products serves as guardrails that enable the company to maintain these key factors.

Other Regulated Markets: Growing at a Steady Pace







Portfolio Maximization and Strategic Partnerships to Drive the Other Regulated Markets Growth

Growth Pivots

Front End Markets

The UK and other front-end markets have returned to their previous levels of growth and profitability

- Portfolio of **40+** launched Products with Top 3 Rank in 1/4th of the Portfolio
- Pipeline of **30+** products to be launched **over next 12-18 months**
- Tapping multiple distribution channels for Rx and OTC products – Direct wholesalers, NHS supplies, and Clinical commissioning groups (CCG)

IP Led B2B Partnerships

- **150+ R&D filings** to build a strong partner led business across **20+ EU Markets**
- Leveraging **10-year** Supply contract with **Arrotex**, **Australia's** leading generic company
- Expansion of product offerings to **New geographies** through portfolio maximization & **Strategic Alliances** to drive growth

Aspiring to Mirror the US Business over the next 4-5 Years ($400 M Revenue)

Growth Markets: Positioned for strong growth via new geographies & new products







Aspiring to grow Emerging markets (Growth & Access) to $ 200m over the next 4-5 years

Deepening Presence in Existing Geographies & Establishing Footprint in New Focus Geographies

Established Geographies

South Africa Business

Portfolio offering of **100+** molecules

Strong relationship with **Dischem** (a Prominent Player) to provide easy access for new products.

Future growth to be driven by **Foraying into tender and Newer Private Market**

Africa Business

African Pharma market is expected to grow at **10%+** with **Branded generic to grow faster** than Originators

Medical field force with coverage of **20,000** Healthcare professionals ensuring a well-established position

Territory **expansion** & Entry into **New Therapies**

New focus Geographies

Focused Expansion

Latin America (LATAM)
One of the historical markets for the group with deep experience

Asia Pacific (APAC)
Significant registered portfolio for re- entry

Commonwealth of Ind States (CIS)
Significant registered portfolio for re- entry

Strategic Partnerships

China
JV with Sihuan with 3 products under registration process

Middle East
Potential to forge partnerships with at least 3 leading companies

Access Markets: A Tender-driven Business; Not a Primary Focus for Strides





Access Markets Key Highlights

- Access markets Revenues continues to be **lumpy** as the business is Tender driven, however this business **recovers for the facility opex**
- Continued focus on CIPs with vendors to reduce COGS and enhance competitiveness

Strides

OneSource: Years of Investments, Time for Fruition

- *Strides announced creation of "OneSource" in Sep'23*
- *An independent Specialty Pharma CDMO*
- *Will unlock value to shareholders*
- *Listing* expected in next ~12 months*

* Transaction subject to approval of Shareholders, Lenders and other applicable Regulatory authorities

Value discovery and Unlocking Potential

- **India's first Specialty Pharma CDMO covering Biologics, complex Injectables and Oral Technologies (Soft-gelatin capsules)**
- **Set to emerge amongst India's Top 5 pure play CDMOs**
- **Full potential of Soft gelatin business residing in Strides unlocked at superior multiple (EV/EBITDA ~17x)**

Value unlock for Strides Shareholders

- Creation of two distinct operating entities with focused executive teams
- Strides shareholders to participate in value discovery by holding 44% in OneSource (**implied value INR 364 per share of Strides**)
- Strides shareholders to receive 1 share of OneSource for every 2 shares of Strides, Swap Ratio of 1:2
- Allows Shareholders and Investors to value both business independently
- Investment strategies aligned with pure play CDMOs
- Efficient capital allocation and focused leadership to drive growth
- Continued focus on superior governance standards

OneSource: Creation of India's first Specialty Pharma Pure Play CDMO

Strides Current Holding	Businesses to be Merged
~31%	**Biologics and high-end drug devices combination** *(Existing Business of Stelis)*
100%	**Oral technologies (Soft Gelatin Capsules)** *(Demerged from Strides Pharma)*
-	**Sterile Injectables** *(Demerged from SteriScience)*

***Strides Shareholders will own 44%** of the economics of OneSource*

OneSource:
India's first specialty pharma pure play CDMO

*The Implied value of proposed Shares issued by OneSource to Strides shareholders is **INR 364 per share***

Resultant Cap Table of OneSource (Currently Stelis)

Category	Pre – Scheme*		Post - Scheme	
	Number of Shares	**% Share Holding**	**Number of Shares**	**% Share Holding**
Promoter and Promoter Group	12,586,085	29.93%	42,321,592	39.00%
Strides Group**	12,929,220	30.74%		
Public	16,541,349	39.33%	66,205,489	61.00%
Total	**42,056,654**	**100.00%**	**108,527,081**	**100.00%**

** 11,089,320 shares held by Strides in Stelis will be cancelled through the Scheme

*The pre-scheme shareholding pattern of Stelis and SteriScience includes, 510,144 shares and 1,649 shares respectively under employee stock options and under other commitments which the management intends to issue before the effectiveness of the scheme.

Financials & Valuation Synopsis:
Valuation of OneSource based on valuation report of PWC and fairness opinion of Jefferies

In $m

	FY24* Revenue	FY24* EBITDA	FY24* Net Debt	Equity Value	Strides Ownership	Strides Value
Soft Gel Business	~65 M	~30%	~35 M	293 M	100%	293 M
SteriScience	~60 M	~28%	~25 M	264 M	-	-
Stelis	~20 M	Breakeven	~55 M	352 M	31%	109 M
OneSource	~145M	~25%	~115 M	909 M	44%	403 M

** Proforma*

Way Forward, Set for Profitable Growth

Way Forward

Target	FY24	FY25
Revenue	~$145 M	~$190 M
EBITDA Margin	~25%	~30%
Net Debt	~$115 M	~$50 M
ROCE %		25%+

Medium Term Outlook

OneSource has potential to double its scale in 3-4 years mainly from the momentum from biologics and high-end drug device combinations in GLP-1 products

EBITDA to FCF generation : 60+%

Net Debt Free by end of FY26

Strides

OneSource: Growth Enablers

The global pharmaceutical and biologics players are leaning towards a partnership model for developing and manufacturing their existing products

Global CDMO market split by product type (2021-28)
Billions of USD



	CAGR% (2022-28)
Biologics	**c.14%**
Small molecules	c.14%
	c.13%

Biologics CDMO market size

	2021	22	23	24	25	26	27	28	
Global (bn USD)	15.3	17.2	19.5	22.3	25.6	29.6	33.8	38.6	
APAC (bn USD)	2.6	3.1	3.7	4.4	5.2	6.2	7.3	8.7	**c.19%**

*Note: *DS: Drug Substance; ** DP: Drug Product*
Source: Frost & Sullivan (2020); Azoth Analytics Report (2022), L.E.K. research and analysis

KEY DRIVERS

Outsourcing to specialized organizations helps global players lower drug development costs, optimize manufacturing networks and improve efficiency.

The industry has high entry barriers due to initial investments in establishing high-end capabilities, long gestation periods, high switching costs for the innovator, and, most importantly, the ability to protect intellectual property rights.

Continued R&D spending will drive significant outsourcing growth (>6% CAGR between 2021-2026, estimated to reach $1.6 trillion), driven by the anticipated launch of novel therapies addressing unmet needs and volume growth from expanding global access to medications.

The outsourcing trend is also being driven by new small pharmaceutical companies, biotechnology startups and virtual pharmaceutical companies who do not have their own developmental and manufacturing facilities

Strides group is combining its assets to build one of most advanced technology led specialty CDMO

Biologics	Soft Gelatin Capsules	Complex & Specialty injectables	Drug-Device Combinations
Microbial biopharmaceuticals	Rx Soft gelatins Out-licensing	Formulation development	
Mammalian biopharmaceuticals	OTC / Consumer Health partnerships	Clinical, analytical and stability studies	
Cell and Gene therapy	Development & Manufacturing services	Fill-finish services	
RNA, Adherent and suspension-based products	Regulatory support	Regulatory support	

Pre-clinical → **Phase 1/2** → **Phase 3** → **Commercial manufacturing**

Our robust capabilities form the bedrock for addressing a substantial market opportunity within the expanding CDMO landscape.

Growth Enablers

Biologics and Drug-Device Combinations

- Fully integrated capabilities from cell line development to commercial manufacturing
- Two manufacturing sites with capabilities in a microbial and mammalian expression system, including wild strains
- USFDA and EMA recently approved Flagship Facility.
- Significant order book to break even in FY24 and fast expand from FY25 as the commercial sales for the partners initiate.

Specialties

Soft Gelatin capsules

- 15+ years of soft gel experience in Rx/Prescription led specialized products.
- One of the largest Global Rx platforms for the soft gels manufactured in technical collaboration with Pharmagel, Italy
- Significant market share (partner-led) in all the commercialized products Globally
- Recent foray into OTC and CDMO led partnerships
- Large scale capacity with 2 billion annual units and planned expansion. Facility approved by US-FDA, MHRA, ANVISA, TGA, WHO, and MCC

Complex and ready to use products

- From the team that delivered significant outcomes with Agila, India's first truly global injectable platform.
- Long term contracts with leading global players across multiple products
- Capabilities to develop and manufacture complex products in differentiated formats including vials, lyophilized vials, Pre-filled Syringes and dry powder.
- Two manufacturing facilities in India with approvals from USFDA, EU-GMP, Health Canada, and UK MHRA.

OneSource Capability Set Snapshot

Five manufacturing facilities have received certification from international authorities, and OneSource is making bigger plans for the future

R&D and Process Development

Biologics

- Cell line and strain development, selection & characterization
- Upstream and downstream process development: Mammalian & Microbial
- Analytical development – physicochemical, bioassay & characterization methods

Speciality:

- Expertise in Ready-to-use and complex injectables including suspensions, microspheres, and liposomes.
- Capabilities and experience in developing products across dosage formats of vials, pre-filled syringes, bags, ampoules, cartridges, and auto-injectors

Soft gelatin capsules

- Installed capacity is one of the largest in the World.
- 4 Encapsulation lines from Pharmagel Italy
- High speed Contact printers to print capsules with High speed camera based inspection system to detect any visual manufacturing defect
- Robust quality and compliance track record with any time audit preparedness
- All regulatory approvals including US-FDA, MHRA, ANVISA, TGA, WHO and MCC amongst others

Biologics , Bengaluru, India

- Approved by USFDA and EU-GMP
- Microbial: Hybrid drug substance manufacture clinical and commercial
- Mammalian: Single-use bags-based drug substance manufacture – clinical & commercial
- Drug Product manufacturing: Vials, PFS & Cartridges. Pen Device Assembly and release as per ISO standards
- Regulatory, Clinical, Validation services, stability studies & misc. support services

Specialty, Bengaluru, India (1)

- State-of-the-art USFDA-approved facility offers a wide range of parenteral drug products with over two decades of experience supplying to the US, Europe, and Australia markets.
- The site has industry-leading expertise in lyophilization techniques and tremendous experience in cycle-time optimization.
- The facility also hosts an autoinjector device line that allows us to offer patient-friendly drug delivery solutions with capacities to produce 16 million autoinjectors annually.

Specialty, Bengaluru, India(2)

- A US-FDA approved dedicated penicillin facility; situated on an area covering 3900 square meters in Bengaluru, India, and caters to global markets including US, Australia & Brazil.
- Supply chain disruptions highlight a key vulnerability for penicillin production worldwide, with increased manufacturing capability for these life-saving drugs becoming imperative for ensuring continued access.
- The facility comprises two sterile dry powder lines with an annual capacity of 32 million units.

1,200+ employees with **200+ scientists** and techno-commercial leaders

Significant investments in quality systems and compliance with industry leading quality governance framework



Strides

Growth lever 1: Biologics and Drug-Device combinations

Our capabilities are tailored to provide development and manufacturing services throughout the lifecycle of biologics and complex products

In the CDMO business, OneSource would offer a fully-integrated biopharmaceutical platform providing one-stop-shop offering for biologics

Truly One-stop Offering

Cell-line Development → **Master and Working Cell Bank** → **Cell Culture Production** → **Filtration and Purification** → **Formulation** → **Fill and Finish** → **Packaging**

Integrated end-to-end provider with high quality tech transfer, process development, manufacturing, fill and finish and release biologics capabilities

Process Development	Drug Substance	Drug Product	Quality & Regulatory Services
• Upstream and downstream development for all clinical phases and injectable formats • Highly streamlined tech transfer approach	• Mammalian and microbial platforms • Single-use bioreactors for lower cost, reduced contamination risk and higher uptime	• Clinical batches to high-speed commercial lines inc. both liquid and lyophilized vials • Single-use manifold systems allowing customizable assemblies	• Highly-experienced regulatory personnel with worldwide regulatory knowhow: a GLP-1 filing completed in <200 days with approval in the first cycle

Single solution for developers seeking a turnkey CDMO partner that can serve across the full project lifecycle

A strong biologics CDMO division with world-class capabilities and capacities enabling cost-effective solutions

One Stop Capabilities

- Pure play biopharmaceutical CDMO covering drug substances capabilities across mammalian and microbial expression systems fully integrated with a wide variety of sterile drug product formats.
- Offers a complete spectrum of services, from cell line tech transfer to clinical and commercial manufacturing.

Flexible and Partner Centric

- Two state-of-the-art facilities, with ~550,000 square feet of Process Development (PD) and manufacturing space for microbial and mammalian programs.
- Tech transfer and scale up activities can be completed in existing facilities whilst bespoke manufacturing expansions are deployed to optimize program timelines.

Mfg. capacities

- 4X 2KL SUB capacity available for Mammalian and 1KL SS capacity for Microbial based products
- Drug product capacities available for all injectable formats (vials, PFS, PFC) and exceed 200 million units per annum
- Agility and space to expand capacity with industry-leading speed whilst catering to bespoke manufacturing requirements

Worldwide Quality and Compliance

- Flagship facility approved by the USFDA, EUGMP
- EU-approved process development capabilities
- Highly experienced quality and regulatory personnel to meet the highest global quality standards, ensure compliance and guide our clients through the regulatory approval process.

Business model for biologics is uniquely poised to recover several income streams until the product approvals are secured

Biologics CDMO Division Business Model

Manufacturing Services Agreements (MSA)

- First part of the CDMO contract which typically includes the technology transfer, process development, process scale and execution of Performance Qualification (PPQ) batches
- Includes the base work required for securing the regulatory approval, and consequently contract for manufacturing
- Typical revenue size in the range of $1-2m for drug product and $4-5m for drug substance

Commercial Sales Agreement (CSA)

- Second part of the CDMO contract, includes the value of business which is secured through the commercial supplies of the products which are developed for the partner under the MSA
- Typically, a duration of CSA would be 3-5 years and is secured by capacity commitment ensuring annuity of revenues

As more MSAs translate into CSAs, the P&L would be able to scale up its business significantly results in high profitability with no major increase in costs

Secured Backlog based on executable CSAs from existing MSAs



OneSource would have a balanced Generics and Innovators' commercial strategy to deliver near and long-term results

Complex Generics & high-end devices

Initial commercial focus leveraging spare capacity.

- Faster ramp up to commercial scale projects and capacity fill
- Lower development risk, de-risking near-term revenue streams
- Leverages group's contacts and goodwill
- Benefits from high market demand for sterile fill-and-finish
- Establishes track record to support innovator BD efforts

Biologics

Long term core strategy with good risk-reward

- Ideal technology set-up to serve a variety of project types
- Opportunity to become a top 5 player in APAC market
- Untapped market opportunity with large CDMOs unwilling to allocate capacity / provide quality service to smaller biotech
- Complex to manufacture products which will benefit from higher margins
- Follow the molecule opportunities, fueling outsized revenue potential once approved

Near-term advantage — **Long-term advantage**

~$1.5m	3-5		$3.5m	5-8
Value per MSA	Years to approvals	*Balanced and flexible approach*	Value per MSA	Years to approvals

Proven Drug Substance Capability

Talented scientific and cross functional team has proven experience in trouble shooting and delivering innovative solutions to clients globally

End-to end-development and manufacturing (DS + DP) of teriparatide biosimilar an *E. coli*-derived recombinant peptide approved by EMA

Successful tech transfer and scale-up of cell culture based adenoviral vector process from 50L to 2000L scale

Developed and validated analytical methods (in-process and release) as well performed ***exhaustive product and impurity characterization*** for peptides, mAbs and recombinant proteins

Successfully developed and scaled up (from 10 L to 1000 L) the technology of multiple ***Insulin analogue molecules***, including extensive method development and characterization.

Drug Substance manufacturing kicked-off in partnership with a global generics major; Mammalian DS development and manufacturing of a biosimilar for one of the largest biologics

First DS project secured

- Partner is a top 5 global Pharma Gx company
- Monoclonal antibody development aimed for global markets, including US, EU and RoW
- Technology transfer in development labs at 10 L, process scale-up to 2 KL, clinical trial material generation batches, PPQ campaign and commercial DS and DP manufacturing

2 DS Projects in advanced negotiations

Unique competitive edge with GLP-1 is a significant factor for future success while the biologics business has also picked up

- From a low base in FY20, we have added several new customers after receiving USFDA approval in FY23 (Two inspections included in CY2022- PAI, Drug Device, and GMP)
- Our business continues to grow as we propel our geographical marketing efforts and attract new partners.
- Our contracting of new manufacturing services agreements (MSAs) has intensified.
- From FY20 to Dec FY24, We secured $74 million in MSAs, of which $43 million were secured in FY24 alone so far. 9 Partners including top global companies have been added to our total unique clientele of 16 after USFDA approval.
- We secured our first significant DS contract with a top 10 global pharmaceutical company for an important product. In addition, the company won several new contracts from our existing partners, demonstrating our execution capabilities for their existing projects with a strong focus on client satisfaction and on-time delivery.
- Made our first commercial shipment, indicating the beginning of commercial supplies for our partnered products. Most Commercial Supply Agreements (CSAs) commence in H2, ensuring this division breaks even on EBITDA in the second half of FY24. In FY25, the division will have a positive PAT.

~$31m
Cumulative value of MSAs won between FY20 and FY23

~$43m
Value of MSAs won in FY24 so far

~$792m
Cumulative value of CSAs for GLP between FY24 and FY32

$282m
Cumulative value CSAs for Non-GLP between FY24 and FY32

~$36m
Value of business under advanced discussions

16+
9 Partners including top global companies onboarded after USFDA approval

OneSource in a sweet spot to capitalize on the upcoming GLP-1 opportunities



(Market Size in $ million as forecasted by Bernstein)

Semaglutide

- Sold as Ozempic® (diabetes) and Wegovy ® (Weight loss/obesity)
- Stelis is partnered with multiple players including 2 with NCE-1 filings in US
- Stelis has strategic advantage of end-to-end drug device assembly with state-of-the-art fill-finish services
- Early commercial revenue opportunity starting 2026

Tirzepatide

- Tirzepatide is a once-weekly GIP receptor and GLP-1 receptor
- It was approved as Mounjaro® by the FDA on May 13, 2022.
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Stelis has partnered with 2 leading global companies

Liraglutide

- Sold as Victoza® (diabetes) and Saxenda ® (Weight loss/obesity)
- Stelis is partnered with multiple players with filings in US & EU
- Stelis has strategic advantage of end-to-end drug device assembly with state-of-the-art fill-finish services

With access through own JVs & CDMO partners, including two first-to-files, Stelis poised to gain significant value from the GLP-1 growth story

Semaglutide

CDMO

- Leading Indian Generic player 1st to file [NCE-1]
- 2 Leading European Generic players

Partnered CDMO

- Licensed to global top 3 generics major – First to file [NCE -1] [Regulated Markets]

- MENA – No.1 Player
- LATAM - No.1 Player

Liraglutide

CDMO

- 6 customers including top Indian and Global players

Tirzepatide

CDMO

- Global Top 2 generics majors

Partnered CDMO

- 1 Leading European player

Strides

Growth lever 2 : Soft Gelatin Capsules

One of the leading global players in soft gelatin technologies with a strong funnel of opportunities and a robust partner led Rx-penetration

The global soft gelatin market is continuously expanding, and the introduction of new products is driving demand for CDMO services. We are amongst the top 5 players globally in SGCs

$11.5b

Global Market Size for
Soft gelatins across generics and NCE-1

$5.5b

North America*- the largest market for soft gelatins

9%

European Union is the fastest region for growth of soft gelatins

US is the largest market and a significant growth pick up is led by the EU and ROW regions

Region	Market size (bn$)	Volume (bn units)	Sales CAGR**	Volume CAGR
NA*	5.5	6.2	6%	-5%
EU Top 5	1.8	2.0	9%	1%
Rest of EU	1.0	2.8	6%	9%
ROW	3.0	9.4	8%	4%
Total	**11.5**	**20.4**	**7%**	**1%**

The new generics opportunity is emerging from the Ex-US regions

Region	Market size (bn$)	Volume (bn units)	Sales CAGR**	Volume CAGR
NA*	877	3604	-6%	-12%
EU Top 5	150	516	3%	3%
Rest of EU	138	378	8%	7%
ROW	706	1410	2%	3%
Total	**1871**	**5908**	**0%**	**-2%**

NCE-1 Opportunity is picking up and only specialized players have the ability to capitalize



a. Increasing intake of soft gelatins in developed and developing countries
b. Increasing use of halal-certified bovine and fish gelatin along with soft gel capsules made from vegetable ingredients such as cellulose gum, modified starch, and other plant gums driving its growth in Islamic countries.
c. Switch to vegetable oil

*NA includes USA & CANADA; **5 years (IMS MAT Q2 2021-2016)*

In technical collaboration with Pharmagel, Italy, our Soft Gelatin Platform under One-Source has been successful in delivering 15 ANDAs, with over 15 years of cumulative Rx soft gel experience.

Our Capabilities for a strong B2B or a CDMO led strategy

Product

- All products developed and manufactured with Global orientation including portfolio for oncology and cytotoxins
- Caters to both Rx and OTC markets with commercialized products having high teen market share
- Capabilities in varying shapes and sizes of SGCs from Oval , Oblong from 2 – 40 oval and 5 to 22 oblong

Plant

- Facility based in Bangalore, India with technological collaboration with Pharmagel, Italy, with 4 Encapsulation lines
- All regulatory approvals, including US-FDA, MHRA, ANVISA, TGA, WHO and MCC, amongst others
- Planned expansion to more than double SGC capacity by FY 24 (2.4 billion plus)

Processes

- High speed Contact printers to print capsules with high-speed camera-based inspection system to detect any visual manufacturing defect
- Robust quality and compliance track record with any time audit preparedness

People

- Dedicated capability pool for soft gelatin expertise
- Focused on domain specific strategy for expansion and operational excellence
- Continuous innovation and new product introduction through in-house capabilities

Amongst the Top 5 Player globally in SGCs with a sizeable presence and a strong pipeline of products to further augment the CDMO business

Strong funnel of opportunities and a robust partner led Rx-penetration

$11.5 B	*Total Soft Gelatin Market with $7.0b in NCE-1*
$4.4 B	*Total Generics opportunity across several products*
$2.5 B	*Market Opportunity for Approved Product Portfolio*
#4	*Largest soft gel manufacturer by volume*
15	*Total approved portfolio*
14	*Products under Development*
5	*NCE-1 coming off-patent in next years*

Plant

- Facility based in Bangalore
- Regulatory approvals: US-FDA, MHRA, ANVISA, TGA, WHO & MCC
- To more than double SGC capacity by FY24 (2.4Bn+)

Product

- Caters to both Rx and OTC markets
- Commercialized products having high teen market share, recently launched Gx Vascepa
- Capabilities in varying shapes and sizes

Client Wins

- Recently concluded multi-year deal with top-4 US private label supplier for 2 OTC SGC products
- In Contract finalization stage with leading OTC global player for supply of 500million units of Ibuprofen SGC
- Potential opportunity in China through our licensed SGC products with a leading Chinese company

Strides

Growth lever 3 : Complex and Specialty Injectables

Significant experience in injectables with wide capabilities makes us a very strong CDMO player for complex and ready to use products

The long-term fundamentals for small molecule complex injectables CDMO opportunities remain intact as more products lose exclusivity and high complexity of products elevates the barrier to entry for new players.

Generic injectables are increasingly considered the next growth engine by large generic players in the US

Most new entrants focus on complex injectables to differentiate themselves from the large incumbents

Nearly every generic player with some scale in the US has about increasing investments in injectables and stepping up on filings at the FDA in the last few years

Injectables seem to be the new mantra for growth in the US market, which has been plagued by competition and pricing squeeze by the wholesalers.

Brands LOE by route of administration ($ billion)[1]

Dosage	Un genericized	2022	2023	2024	2025	2026	2027	Total
Simple injectables		3.2	0.2	0.6	0.5	1.0	3.0	8.6
Complex Injectables	7.8	1.6		0.8		1.1	0.3	12.1
Inhalation	4.2		0.2		1.3		2.5	8.3
Others	0.8	0.3	0.2	0.1	0.6	0.6	0.8	2.9

1. *Source: Evaluate, Bernstein estimates and analysis LOE - Loss of exclusivity; Sales in the year before LOE*

The current environment in injectables presents opportunity for new players that can scale with capabilities

SEVERE INJECTABLE SHORTAGES PERSISTING – HITTING A 10-YEAR HIGH – MAJOR LACK OF SUPPLY RELIABILITY

INCREASED SCRUTINY FROM REGULATORS ON FACILITY INSPECTIONS EMERGING POST COVID

ABILITY TO OPERATE LARGE-SCALE, HIGH-QUALITY MANUFACTURING KEY TO SECURED SUSTAINABLE GROWTH

ACUTE SHORTAGES DRIVING CHANGE IN MARKET BEHAVIOURS WITH NEW PLAYERS LIKE CIVICA DISRUPTING STATUS QUO

OPPORTUNITY FOR EMERGING PLAYERS THAT HAVE ABILITY TO OPERATE AT SCALE

One of the largest platform for sterile injectables with strong capabilities across dosage formats

DOSAGE FORMATS

- Liquid Vials
- Lyophilized Vials
- Auto-injectors
- Pre-Filled Syringes(PFS)

Bengaluru, Site 1
General Injectables

- State-of-the-art USFDA approved facility offers a wide range of parenteral drug products with over two decades of experience supplying to the US, Europe and Australia markets.
- The site has industry-leading expertise in lyophilization techniques and tremendous experience in cycle-time optimization.
- The facility also hosts an autoinjector device line that allows us to offer patient-friendly drug delivery solutions with capacities to produce 16 million autoinjectors annually.

Bengaluru, Site 2
Dedicated to Penicillins

- A US-FDA approved dedicated penicillin facility; situated on an area covering 3900 square meters in Bengaluru, India and caters to global markets including US, Australia & Brazil.
- Supply chain disruptions highlight a key vulnerability for penicillin production worldwide, with increased manufacturing capability for these life-saving drugs becoming imperative for ensuring continued access.
- Facility consists of two sterile dry powder lines, with an annual capacity of 32 million units.

R&D Capabilities

- Strong R&D team with 100+ years of domain expertise and rich experience in injectables
- Expertise in Ready-to-use and complex injectables including suspensions, microspheres, and liposomes.
- Capabilities and experience in developing products across dosage formats of vials, pre-filled syringes, bags, ampoules, cartridges, and auto-injectors

CDMO (One-Source) platform: Building a global CDMO platform with 2 distinct segments - high margin IP-led CDMO business; & a tactical CMO business (used to ensure efficient capacity utilization)

- **In-house development of ANDAs** on behalf of the partners, with 5 launches in the US market and another 4 planned in the next 6 months
- Targeted B2B strategy for the portfolio with **more secured economics and shorter working capital cycles**
- Business model includes secured margins on transfer price, **with additional profit sharing and royalty earnings**

- **CMO contracts with legacy partners**, as part of the acquisition of the manufacturing sites
- Pure play CMO with revenues at transfer price value, ensuring a **fully loaded COGS + margin model**
- IP ownership is with the contract giver, with **Steriscience bringing in the manufacturing expertise**

We have invested over $200m investments to build end-to-end fully integrated service offering, along with the capacity and agility to handle almost any level of client demand.

One-Source will target a global opportunity with very few players that attract industry-leading multiples

Trends in CDMOs

Flexible CDMOs support pharmaceutical companies at all stages of the process of making medicines shifting their business model

CDMO M&A is on the rise, trailblazing with new manufacturing capabilities and scale

CDMO value chain is moving toward a “one-stop-shop” service portfolio with CDMO value chain becoming broader

CDMOs at scale have the purchasing power to move into new areas quickly, to extend their business model broadly

Structural shift to large molecules, the introduction of new modalities, deep pipeline, and R&D funding is expected to drive solid double-digit end-market sales growth

Leading Global players and their valuations

Segment	API	FDF	Biologics	Revenue ($b)	Market Cap ($b)	EV/EBITDA (x)
Wuxi		◉	◉	2.3	11.5	14
Lonza	◉	◉	◉	7.5	37.3	22
Samsung		◉	◉	2.8	44.2	39
Catalent		◉	◉	4.3	9.3	9
Thermofisher		◉	◉	42.9	208.2	23

Top Indian players and their valuations

Segment	API	FDF	Biologics	Revenue ($m)	Market Cap ($b)	EV/EBITDA (x)
Divis	◉			955	11.7	49.8
Suven	◉	◉		166	2.0	27.8
Piramal	◉	◉	◉	882	2.2	21.8
Gland		◉	◉	518	3.9	28.7
Syngene		◉	◉	398	3.6	29.7
One-Source (FY25)		◉	◉	190	1.0* (listing)	17x (1y Fwd)

** Basis independent valuation as announced*

Strides

Thank You

Strides

Delivering with **Momentum**

Q1FY25 Results | July 29, 2024

Strides Pharma Science Limited

Safe Harbor

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", “seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements“. These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m Revenue Growth of 16.7% YoY with an EBITDA Margin of 20%

Growth recorded across all major markets

	Q1FY25	Q1FY24	YoY
Revenues	₹10,875m	₹9,320m	16.7% ↑
Gross Margins	₹6,671m	₹5,470m	21.9% ↑
Gross Margin (%)	₹61.3%	58.7%	264bps ↑
EBITDA	₹2,170m	₹1,686m	28.7% ↑
EBITDA Margin (%)	20.0%	18.1%	187bps ↑
Adj. PAT	₹839m	₹295m	↑
Reported PAT	₹683m	-₹94m	↑
Adj. EPS	₹9.1	₹3.3	↑
Reported EPS	₹7.6	-₹0.8	↑

Adjusted PAT = PAT from continuing operations without JV share and exceptional items

Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook.

The company achieved critical thresholds of 20% EBITDA margin, ₹683m of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business.

The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes.

Arun Kumar
Founder and Executive Chairperson

Badree Komandur
MD and Group CEO

Stable Revenue Growth with Improved Margins

Q1FY25 Adjusted PAT at ₹839m and Reported PAT at ₹683m

Strides

xx Revenue in $M

Total Revenue (₹/$M)



- Linearity in revenue with higher focus on margin growth

Gross Margin



- Quality of business improved on the back of superior portfolio mix
- Gross Margin improved to 61.3% in Q1FY25

EBITDA & EBITDA Margin



- Q1FY25 EBITDA margin in line with FY25 outlook at 20.0%

Adj. PAT (₹M)



Reported PAT (₹M)



- Significant drop in loss pick up with OneSource (erstwhile Stelis) delivering its second consecutive EBITDA positive quarter

Strides Reaffirms FY25 Outlook

PARAMETERS	FY25 OUTLOOK	COMMENTS	Q1FY25 STATUS UPDATE
REVENUE	CONTINUING BUSINESS REVENUE TO GROW AT 12-15% YoY	Growth is targeted to come in H2FY25 based on global product launches	Revenue grew by 16.7% YoY, ahead of FY25 outlook
EBITDA MARGIN	AIMING FOR AN EBITDA OF ₹9,500M – ₹10,000M	EBITDA margin to be in the range of 20%-22%	Achieved EBITDA of ₹2,170m for the quarter (H1 being our leaner operating half) EBITDA margin of 20% in line with the FY25 outlook
NET DEBT TO EBITDA	NET DEBT TO EBITDA <2.0x AS OF MARCH'25	Efficient working capital cycle and operating cashflow to aid debt reduction	Net Debt to EBITDA at 2.3x in Q1FY25 on annualized basis gives us strong confidence to achieve outlook
US BUSINESS	US REVENUE TO BE IN RANGE OF $285-$300M	Poised to achieve ~$400m by FY27-28	US revenues increased from $57m in Q1FY24 to a historic high of $70m in Q1FY25 We are encouraged by our strong Q1 performance in spite of H1 being a leaner operating half

US Market

- US Revenues at a Historic High of $70m in Q1FY25, Grew 24.5% YoY
- Reaffirming FY25 Revenue Outlook of $285m - $300m
- The US Business Poised to Achieve the ~$400m Objective by FY27-28

US Revenues at a Historic High of $70m in Q1FY25, grew 24.5%YoY

Reaffirming outlook of $285m - $300m for FY25

Strides

Year-on-Year Comparison (₹/$M)



Last Four Quarter Trend (₹/$M)



YoY growth are on ₹ reported numbers

Highlights

- Q1FY25 Revenues at ₹5,851m ($70m), grew 24.5% YoY
- First full quarter of gSuprep with ~30% market share
- Received 3 new product approvals
- Launched 1 significant dormant product from the acquired Endo portfolio
- Total commercialized products at 67
- Sustained market share across the product portfolio enabled YoY growth
- Disciplined and calibrated portfolio launch approach led to improved profitability
- Ranked amongst the top 3 in 35 products enjoying a market-leading position for several years, contributing ~75% of our total US revenues
- Industry-leading customer service levels amongst generic pharma players leading to near-zero Failure-To-Supply penalties

Business Outlook

Generics

- 60 products have been identified from our dormant ANDAs which are under various regulatory phases of PAS (prior approvals supplements) for source change and cost leadership to be relaunched over the next 3 years to achieve the stated objective of $400m generics revenue

Beyond Generics

- The company has invested in new segments of Control Substances Nasal Sprays and 505 (b) (2) as part of a longer-term strategy beyond the ~$400m generics revenue objective.
- We expect to file 2 products with the USFDA by Q1FY26

Other Regulated Markets

- Other Regulated Markets Revenues at $41m, Grew by 17.8% YoY
- Portfolio Maximization and Increased Focus on B2B Partnerships will Continue to Drive Growth

Other Regulated Markets Revenues at $41m, grew 17.8% YoY

Year-on-Year Comparison (₹/$M)



Last Four Quarter Trend (₹/$M)



YoY growth are on ₹ reported numbers

Highlights

- All regulated markets ex-US form part of the Other Regulated Markets
- Q1FY25 Revenues at ₹3,385m ($41m), grew 17.8% YoY
- Robust demand for key products coupled with new long-term supply contracts, has significantly propelled growth within the UK and Nordic market
- Strong customer advocacy and dependable supply enabled us to expand our customer base

Business Outlook

- Significant growth in this segment is expected in H2FY25 driven by new product approvals and partner launches
- Expansion of product portfolio and new customer acquisitions to drive growth
- Conversion of the existing strong funnel of new opportunities to deliver growth
- Continued momentum in filings and approvals to fast-track growth

Growth and Access Markets

- Growth Markets Positioned for Strong Growth via Geographical Expansion & New Products

Growth Markets Revenues at $13m, grew 41.2% YoY
Access Markets Revenues remain lumpy at $7m

Year-on-Year Comparison (₹/$M)



Last Four Quarter Trend (₹/$M)



YoY growth are on ₹ reported numbers

Growth Markets

- Growth Markets includes Africa operations and new geographies of LATAM, MENA, CIS, APAC
- Q1FY25 Revenues at ₹1,098m ($13m)

Business Outlook :

- Significant regulatory filings in new territories have commenced however the regulatory timelines in most markets are longer
- Growth Markets will have lumpy quarters until business stabilizes in next two years
- Focus on portfolio maximization strategies and astute channel partner expansion will drive the future growth

Access Markets

- Q1FY25 Revenue at ₹541m ($7m)
- Continued focus on CIPs with vendors to reduce costs and enhance competitiveness
- Contribution to overall revenues continues to be small

Business Outlook :

- Global Funds allocation was muted in FY24. However, Strides received a higher allocation in FY25 on the back of superior DIFOT (Delivery In Full On Time)
- Access Markets revenues continue to be lumpy while we expect a stronger H2FY25

Financial Performance

- Strong Financial Discipline Enabled Profitability and Cashflow Generation

Income Statement – Q1FY25

Income statement (₹m)					
Particulars	**Q1 FY25**	**Q1 FY24**	**YoY**	**Q4 FY24**	**QoQ**
I. Revenue	**10,875**	**9,320**	**16.7%**	**10,583**	**2.8%**
II. Material Costs	4,204	3,850		4,162	
III. Gross Margin (I- II)	**6,671**	**5,470**	**21.9%**	**6,421**	**3.9%**
Gross Margin %	**61.3%**	**58.7%**	**264bps**	**60.7%**	**67bps**
a. Personnel Cost	2,122	1,675		1,992	
b. Other Opex	2,379	2,109		2,389	
IV. Total Opex (a+b)	**4,501**	**3,784**		**4,381**	
V. EBITDA (III-IV)	**2,170**	**1,686**	**28.7%**	**2,040**	**6.4%**
EBITDA Margin %	**20.0%**	**18.1%**	**187bps**	**19.3%**	**68bps**
c. Depreciation and amortisation	486	596		498	
d. Net Finance Cost	677	697		680	
e. Exceptional items – net (gain) / loss	37	60		81	
f. JV share of loss	118	329		486	
VI. Profit/ (loss) before tax (V-c-d-e-f)	**852**	**3**		**296**	
g. Tax	169	97		193	
VII. Profit/(loss) after tax from continuing operations (	**683**	**(94)**		**104**	
h. Profit from Discontinued Operations	-	-		1	
VIII. Profit / (loss) for the period (VII+h)	**683**	**(94)**		**104**	**-**

Reconciliation of EBITDA (₹m)				
Particulars	**Q1FY25**	**Q1 FY24**	**Q4FY24**	
Profit before exceptional items & tax	1,007	392	863	
Less: Finance income	127	67	122	
Add : Depreciation and Amortization	486	596	498	
Add : Finance costs	804	764	802	
Consolidated EBITDA as per press note	**2,170**	**1,686**	**2,040**	

Net Debt reduced by ₹367m in Q1FY25, Net Debt at ₹19,983m

Current Net Debt to EBITDA stands at 2.3x – Tracking ahead of the outlook of <2x

Particulars (In ₹m)	Mar'24	Jun'24
Working Capital Loans	15,742	14,938
Long Term Loans	8,403	8,795
Gross Debt	**24,145**	**23,733**
Cash and Cash Equivalents*	-3,795	-3,750
Net Debt	**20,350**	**19,983**

** Cash and cash equivalents ₹ 3,750m consists of cash balance ₹ 1,798m deferred consideration receivable₹ 773m and deposits of ₹ 1,180m*

Finance cost (In ₹m)	FY24	Q1FY25
Interest Cost on Borrowings (A)	2,544	647
Other Finance Charges (B)	601	157
Finance Income (C)	353	127
Net Finance Cost (A+B-C)	**2,791**	**677**

- Credit Rating Upgrade to "CARE A, Stable " in Q1FY25
- Significant investments in Q1FY25 on working capital and capex for future growth

Outlook for FY25

- Aiming for Net Debt reduction of ₹5,000m (including debt pushdown of ~₹2,800m to OneSource)
- Our focus on cash-to-cash cycle improvements and operating cash generation will enable us to achieve the outlook of Net Debt/EBITDA
- Continuing Capex of ₹1,500m - ₹2,000m to be funded from internal accruals

Key Balance Sheet Ratios

Strides

Net Debt to Equity (x)



Net Debt to EBITDA (x)



Cash to Cash Cycle (Days)



Current Ratio (x)



RoCE (%)



Fixed Asset Turnover Ratio (x)



Q1FY25 ROCE and Net Debt to EBITDA ratios are on annualized basis
All other ratios are computed on TTM basis
**Capital Employed = Equity + Net Debt*

Strides

OneSource Specialty Pharma Ltd

(formerly known as Stelis BioPharma Ltd)

OneSource – Q1FY25 Updates

Strides

OneSource (erstwhile Stelis) – Biologics and Drug-Device Combinations Business

- Biologics division (Stelis) achieved revenue at $9.4m in Q1FY25, which Is ~45% of FY24 total revenue
- Recorded an adjusted EBITDA of $1.2m, second consecutive quarter of being EBITDA positive
- Strong H2 with commercial supplies for GLPs to commence

Steriscience – Complex and Specialty injectables (CMO+CDMO)

- Complex and Specialty injectables (CMO+CDMO) business on track to achieve targeted EBITDA

Soft Gelatin Capsules (Strides Business Moving to OneSource)

- On track to achieve targeted EBITDA

OneSource – FY25 Outlook

- Aiming for Revenue in range of $175-190m
- Aiming for EBITDA in range of $60-65m

Update on OneSource Listing

Received "No objection"* from Stock Exchanges (NSE and BSE) on 21st May'24, post clearance from SEBI

NCLT filing admitted, expecting NCLT orders for conducting Creditors/Shareholders meeting shortly

**Received "No objection" from NSE and "No adverse observations" from BSE*

OneSource – Q1FY25 Key Business Updates

Strides

OneSource (erstwhile Stelis) - Biologics and Drug-Device Combinations Business

Drug Device Combination (DDC)	Drug Substance
• Onboarded 2 additional customers including a top 3 global generics company (total 15 logos) • Inhouse PTH DDC approved by UK MHRA – to be marketed in partnership with a leading European Gx player	• Onboarded top 3 Global Animal Health companies for a novel biologics with a 10 yrs supply contract – first significant Drug Substance win
• Significant upticks in RFPs (15) issued in Q1FY25, 2.5x of standard RFPs	
• Concluded successful national audits from S. Arabia & Taiwan, including the successful European approval of the facility in Q4FY24	

Steriscience – Complex and Specialty injectables (CMO+CDMO)

- Onboarded one of N.America's largest buying groups for 3 IP owned products in a multi year supply contract
- Proprietary DDC product licensed to one of the largest generic player in EU5

- 4 RFPs issued in Q1FY25
- Successful closure of US FDA audit with a VAI status

Soft Gelatin Capsules (Strides Business Moving to OneSource)

- Manufacturing capacity expanded from 1 Bn to 2.4 Bn units in anticipation of increased CDMO demand

- Previously secured CDMO contracts from top 2 global private labelers will commence in H2FY25

Q1FY25 Earnings Call Details

Strides

Strides

invites you to interact with the senior management on Q1FY25 Performance

July 29, 2024

3:30pm IST / 11:00am BST / 6:00am EDT / 6:00pm HKT

Participants from the Management would be:

Arun Kumar
Founder & Executive Chairperson

Badree Komandur
Managing Director & Group CEO

Vikesh Kumar
Group CFO

Click here to pre-register and join without the operator

Join through an operator using dial in numbers

India Primary	+91 22 6280 1434 / +91 22 7115 8838		
USA	18667462133	Singapore	8001012045
UK	08081011573	Hongkong	800964448

Thank You !

Strides Pharma Science Limited
CIN: L24230MH1990PLC057062

Corporate Office
Strides House, Bannerghatta Road, Bengaluru - 560 076, India
Tel.: +91 80 6784 0000/ 6784 0290
Email: Investor-Relations@strides.com

Registered Office
201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India, Tel.: +91 22 2789 2924/2789 3199
Website: www.strides.com